Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11884919
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
granted -
US 11883528
Compositions and methods for treating pulmonary edema or lung inflammation
granted -
US 11883468
Compositions and methods to suppress tumor growth in bone, prevent cachectic muscle loss, and preserve skeletal integrity
granted -
US 11883420
Sting agonists for treating bladder cancer and solid tumors
granted -
US 11884707
Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
granted -
US 11885806
Method for depleting malignant T-cells
granted -
US 11883386
Prolyl hydroxylase inhibitors and methods of use
granted -
US 11884920
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted -
US 11884657
PI-kinase inhibitors with anti-infective activity
granted -
US 11884715
Activin receptor type IIB variants and methods of use thereof
granted -
US 11884731
Vedolizumab for the treatment of fistulizing Crohn's disease
granted -
US 11884925
Synthetic immunomodulation with a CRISPR super-repressor in vivo
granted -
US 11884736
Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)
granted -
US 11884746
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
granted -
US 11884945
Methods for purification of arylsulfatase A
granted -
US 11885861
3-dimensional representations of post-contrast enhanced brain lesions
granted -
US 11884932
In vitro production of medial ganglionic eminence precursor cells
granted -
US 11885817
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11883441
Compositions and methods for inhibiting seizures
granted -
US 11884740
Anti-CD20 antibody compositions
granted -
US 11883433
Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof
granted -
US 11883432
Chimeric antigen receptor system with adaptable receptor specificity
granted -
US 11884647
Compounds and methods for targeting pathogenic blood vessels
granted -
US 11884718
Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
granted -
US 11883492
Combination treatment of chemoresistant cancers
granted -
US 11884710
Peptide compounds and methods of use in wound healing
granted -
US 11884672
Modulators of alpha-1 antitrypsin
granted -
US 11882920
Systems, devices and methods for styling hair
granted -
US 11883423
Nucleobase analogue derivatives and their applications
granted -
US 11883431
T-cells modified to overexpress PHF19
granted -
US 11883359
Adapter for use in a planetary mixer
granted -
US 11883408
Reboxetine to treat narcolepsy
granted -
US 11884748
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
granted -
US 11883475
Infectious Plasmodium sporozoites grown in vitro
granted -
US 11883223
Hepatic inflammation analysis with dynamic PET
granted -
US 11884930
Method of inactivating a glucocorticoid receptor gene in an isolated cell
granted -
CA 3256289
MÉTHODES PERMETTANT DE FAVORISER LA CROISSANCE DE RATTRAPAGE SAINE
granted -
CA 3259243
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2
granted -
CA 3263005
POLYPEPTIDES SE LIANT À UN ÉPITOPE SPÉCIFIQUE DU RÉCEPTEUR FC NÉONATAL
granted -
CA 3259252
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3
granted -
CA 3259391
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
granted -
WO 2024023766
POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K
granted -
US 11891638
Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)
granted -
US 11890272
Non-sedating dexmedetomidine treatment regimens
granted -
US 11891616
Transgene cassettes designed to express a human MECP2 gene
granted -
US 11891426
CD19 variants
granted -
US 11891402
Compositions and methods for treating cancer
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.